New combo therapy and advanced scans aim to better detect and treat prostate cancer
NCT ID NCT03860987
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 31 times
Summary
This study tests a combination of three hormone-blocking drugs (enzalutamide, abiraterone, and standard hormone therapy) in men with newly diagnosed prostate cancer that hasn't spread. Researchers also use advanced PET/CT scans with a special tracer to see if they can better detect and monitor the cancer. The goal is to improve treatment before surgery and learn more about how the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATE SENSITIVE PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.